Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALAXIES Lung-301 in untreated PD-L1-high advanced non-small cell lung cancer
jRCT2051240051Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Belrestotug + dostarlimab with Placebo + pembrolizumab (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events and serious adverse events and Incidence of TEAEs/SAEs leading to dose withdrawal or treatment discontinuation. Started Jun 2024; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051240051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240051.